Evidence map›Paper›PMID 36386226›Full record

ArticleFrontiers in pharmacology2022

Synthesis and appraisal of dalbergin-loaded PLGA nanoparticles modified with galactose against hepatocellular carcinoma:

Anurag Kumar Gautam, Pranesh Kumar, Biswanath Maity, Ganesh Routholla, Balaram Ghosh, Kumarappan Chidambaram, M Yasmin Begum, Adel Al Fatease, P S Rajinikanth, Sanjay Singh and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Liver cancer wars: plant-derived polyphenols strike back.Medical oncology (Northwood, London, England) · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anurag Kumar GautamDepartment of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, India.
Pranesh KumarDepartment of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, India.
Biswanath MaityCentre of Biomedical Research, SGPGIMS Campus, Lucknow, Uttar Pradesh, India.
Ganesh RouthollaDepartment of Pharmacy, BITS-Pilani Hyderabad Campus Hyderabad, Hyderabad, India.
Balaram GhoshDepartment of Pharmacy, BITS-Pilani Hyderabad Campus Hyderabad, Hyderabad, India.
Kumarappan ChidambaramDepartment of Pharmacology and Toxicology, School of Pharmacy, King Khalid University, Abha, Saudi Arabia.
M Yasmin BegumDepartment of Pharmaceutics, King Khalid University, Abha, Saudi Arabia.
Adel Al FateaseDepartment of Pharmaceutics, King Khalid University, Abha, Saudi Arabia.
P S RajinikanthDepartment of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, India.
Sanjay SinghDepartment of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, India.
Sudipta SahaDepartment of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, India.
Vijayakumar M RDepartment of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a common malignancy which affects a substantial number of individuals all over the globe. It is the third primary cause of death among persons with neoplasm and has the fifth largest mortality rate among men and the seventh highest mortality rate among women. Dalbergin (DL) is described to be effective in breast cancer

Indexed as

dalbergingalactose decorated nanoparticlesHCCliver cancer targetingtargeted nanoparticles

Identifiers

PMID36386226
PMCPMC9650263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.